[go: up one dir, main page]

BR0208183A - Peptide modified by wt1 - Google Patents

Peptide modified by wt1

Info

Publication number
BR0208183A
BR0208183A BR0208183-0A BRPI0208183A BR0208183A BR 0208183 A BR0208183 A BR 0208183A BR PI0208183 A BRPI0208183 A BR PI0208183A BR 0208183 A BR0208183 A BR 0208183A
Authority
BR
Brazil
Prior art keywords
peptide
vaccine
peptide modified
active
ingredient
Prior art date
Application number
BR0208183-0A
Other languages
Portuguese (pt)
Inventor
Haruo Sugiyama
Original Assignee
Haruo Sugiyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama filed Critical Haruo Sugiyama
Publication of BR0208183A publication Critical patent/BR0208183A/en
Publication of BRPI0208183B1 publication Critical patent/BRPI0208183B1/en
Publication of BRPI0208183B8 publication Critical patent/BRPI0208183B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

"PEPTìDEO MODIFICADO POR WT1". A presente invenção refere-se a um peptídeo de antígeno de câncer compreendendo a seq³ência de aminoácido seguinte: Cys Tyr Thr Trp Asn Gln Met Asn Leu (N<0> de ID de Seq³ência 3), uma vacina para câncer tendo isto como seu ingrediente ativo, e uma vacina de DNA tendo como seu ingrediente ativo DNA que codifica este peptídeo."WT1 MODIFIED PEPTIDE". The present invention relates to a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this as its ingredient active, and a DNA vaccine having as its active ingredient DNA encoding this peptide.

BRPI0208183 2001-03-22 2002-03-22 wt1 modified cancer antigen peptide and cancer vaccines BRPI0208183B8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001083250 2001-03-22
PCT/JP2002/002794 WO2002079253A1 (en) 2001-03-22 2002-03-22 Wti modified peptide

Publications (3)

Publication Number Publication Date
BR0208183A true BR0208183A (en) 2004-03-02
BRPI0208183B1 BRPI0208183B1 (en) 2018-08-28
BRPI0208183B8 BRPI0208183B8 (en) 2021-05-25

Family

ID=18939092

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208183 BRPI0208183B8 (en) 2001-03-22 2002-03-22 wt1 modified cancer antigen peptide and cancer vaccines

Country Status (12)

Country Link
US (2) US20040097703A1 (en)
EP (1) EP1371664B1 (en)
JP (2) JP3728439B2 (en)
KR (1) KR100863853B1 (en)
CN (1) CN1281625C (en)
AT (1) ATE383375T1 (en)
BR (1) BRPI0208183B8 (en)
CA (1) CA2440303C (en)
DE (1) DE60224508T2 (en)
ES (1) ES2298353T3 (en)
TW (1) TWI318630B (en)
WO (1) WO2002079253A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1103564E (en) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc CANCER ANTIGENS BASED ON WT1 TUMOR SUPPRESSOR GENE PRODUCT
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International Novel method of inducing antigen-specific t cells
JP2003243616A (en) 2002-02-20 2003-08-29 Seiko Epson Corp Method for manufacturing semiconductor device
EP1536009B1 (en) 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restricted cancer antigen peptide
US7342092B2 (en) * 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
EP1548028B1 (en) * 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
ES2332590T3 (en) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. PEPTIDIC DIMERO.
CN1842603B (en) 2003-06-27 2013-09-11 株式会社国际癌症免疫研究所 Method of selecting wt1 vaccine adaptive patient
CN100513563C (en) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 WT 1-derived HLA-DR-binding antigenic peptide
ATE462003T1 (en) * 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc CANCER ANTIGEN PEPTIDES DERIVED FROM WT1
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
SI1988163T1 (en) * 2006-02-22 2012-09-28 Int Inst Cancer Immunology Inc Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2670658A1 (en) * 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
CA2677075C (en) 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
CN103374576A (en) 2007-03-05 2013-10-30 株式会社癌免疫研究所 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
KR101610664B1 (en) 2007-12-05 2016-04-08 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Cancer vaccine composition
KR20140009168A (en) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Method for activating helper t cell
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
EP2802347B1 (en) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
ES2655031T3 (en) 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Transdermal preparation of cancer antigenic peptide
CN104797711B (en) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 antigen-specific helper T cell receptor gene
JP6530192B2 (en) 2012-12-17 2019-06-12 大塚製薬株式会社 Method of activating helper T cells
CA2898099C (en) * 2013-01-15 2025-09-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6250288B2 (en) * 2013-01-30 2017-12-20 株式会社医学生物学研究所 T cell receptor and use thereof
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
KR20140100419A (en) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 Wt1 peptide cancer vaccine composition for transdermal administration
JP6512567B2 (en) 2013-02-05 2019-05-15 日東電工株式会社 WT1 peptide cancer vaccine composition for transdermal administration
KR102045029B1 (en) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 Wt1 peptide cancer vaccine composition for mucosal administration
CA2905588C (en) 2013-03-12 2018-11-06 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
EP2980097A4 (en) 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of erap1
CA2907782C (en) 2013-03-29 2021-01-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
JP6634287B2 (en) 2013-05-13 2020-01-22 株式会社癌免疫研究所 Predicting the clinical efficacy of immunotherapy
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
EP3199175B1 (en) 2014-09-27 2022-03-23 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical composition for injection
JP7209963B2 (en) 2016-11-30 2023-01-23 住友ファーマ株式会社 WT1 helper peptide and its combination with cancer antigen peptide conjugate
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Wt1 cancer antigen peptide and peptide conjugate body containing same
AU2019349329A1 (en) 2018-09-28 2021-04-29 Sumitomo Pharma Co., Ltd. Injectable composition
TWI851607B (en) 2018-10-05 2024-08-11 日商癌免疫研究所股份有限公司 Preventive or therapeutic drugs for benign tumors
TW202528332A (en) 2019-02-28 2025-07-16 日商住友製藥股份有限公司 Method for selecting a subject for whom the effect of a pharmaceutical composition for treating or preventing cancer can be expected
AU2021272616A1 (en) 2020-05-12 2022-12-15 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition for treating cancer
CN111647066B (en) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 WT1 polypeptide tumor inhibitor
MX2024001843A (en) 2021-08-12 2024-05-16 Int Inst Cancer Immunology Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING OR PREVENTING CANCER.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (en) 1984-07-06 1986-01-30 Green Cross Corp:The Enhancer for cancer immunotherapy
JP3393867B2 (en) 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー Localization and characterization of the Wilms oncogene
WO1995016464A1 (en) 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
ATE332710T1 (en) * 1995-06-01 2006-08-15 Kishimoto Tadamitsu GROWTH INHIBITOR AGAINST LEUKEMIC CELLS CONTAINING ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST WILMS TUMOR
JP3904260B2 (en) 1995-06-01 2007-04-11 岸本 忠三 Leukemia cell growth inhibitor comprising an antisense oligonucleotide derivative against Wilms tumor gene (WT1)
PT851934E (en) * 1995-09-19 2006-11-30 Bayer Bioscience Gmbh Plants which synthesise a modified starch, process for the production thereof and modified starch
JP4789095B2 (en) 1997-07-16 2011-10-05 治夫 杉山 Solid tumor therapeutic agent comprising an expression inhibitor against Wilms tumor gene (WT1)
US20030092656A1 (en) * 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
PT1103564E (en) * 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc CANCER ANTIGENS BASED ON WT1 TUMOR SUPPRESSOR GENE PRODUCT
KR100752065B1 (en) * 1998-09-30 2007-08-28 코릭사 코포레이션 VT1-specific immunotherapy compositions and methods
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) * 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
NZ512890A (en) 1999-01-12 2003-09-26 Smithkline Beecham Biolog S Antiviral agents including nucleoside analogues active against hepatitis B virus (HBV)
PT1031346E (en) 1999-01-27 2002-09-30 Idea Ag NOT INVASIVE VACCINATION THROUGH SKIN
DE60026666T2 (en) 1999-07-22 2006-11-09 Dainippon Sumitomo Pharma Co., Ltd. Induction of antigen-specific T cells by interferon
JP2001089389A (en) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd Inducers for antigen-specific T cells
NZ521430A (en) 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (en) * 2001-09-28 2008-02-13 Institute Of Can International Novel method of inducing antigen-specific t cells
EP1536009B1 (en) 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restricted cancer antigen peptide
US7342092B2 (en) 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
ES2332590T3 (en) 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. PEPTIDIC DIMERO.
CN1842603B (en) 2003-06-27 2013-09-11 株式会社国际癌症免疫研究所 Method of selecting wt1 vaccine adaptive patient
CN100513563C (en) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 WT 1-derived HLA-DR-binding antigenic peptide
ATE462003T1 (en) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc CANCER ANTIGEN PEPTIDES DERIVED FROM WT1

Also Published As

Publication number Publication date
TWI318630B (en) 2009-12-21
JP3819930B2 (en) 2006-09-13
US20090325886A1 (en) 2009-12-31
JPWO2002079253A1 (en) 2004-07-22
KR100863853B1 (en) 2008-10-15
US20040097703A1 (en) 2004-05-20
CN1281625C (en) 2006-10-25
JP3728439B2 (en) 2005-12-21
ES2298353T3 (en) 2008-05-16
JP2006034296A (en) 2006-02-09
DE60224508T2 (en) 2008-12-24
HK1070078A1 (en) 2005-06-10
EP1371664A4 (en) 2006-03-22
DE60224508D1 (en) 2008-02-21
KR20030084970A (en) 2003-11-01
CA2440303A1 (en) 2002-10-10
BRPI0208183B1 (en) 2018-08-28
ATE383375T1 (en) 2008-01-15
WO2002079253A1 (en) 2002-10-10
CA2440303C (en) 2013-03-19
EP1371664B1 (en) 2008-01-09
BRPI0208183B8 (en) 2021-05-25
US8105604B2 (en) 2012-01-31
EP1371664A1 (en) 2003-12-17
CN1531553A (en) 2004-09-22

Similar Documents

Publication Publication Date Title
BR0208183A (en) Peptide modified by wt1
BR0208636A (en) Therapeutic agent for chronic arthritic diseases of childhood-related diseases
TW200602071A (en) Methods for preventing and treating alzheimer&#39;s disease (ad)
BR0207157A (en) O-desmethyl-venlafaxine succinate salt
BR0209434A (en) Antimicrobial Peptides and Compositions
CY1107146T1 (en) METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER&#39;S DISEASE (AD)
ATE118352T1 (en) CAUSES OF MYSTERIOUS SWINE DISEASE, VACCINE COMPOSITIONS AND DIAGNOSTIC KITS.
BR0211296A (en) Immunogenic peptide derived from subgroup a or b vrs protein g, nucleic acid sequence, pharmaceutical composition, polyclonal or monoclonal antibodies, diagnostic kit, use of an immunogenic peptide, and, conjugate
BR9811094A (en) Therapeutic agent for lymphatic tumors
DE60043620D1 (en) MAGE-A1 PEPTIDES PRESENTED BY CLASS II HLA MOLECULE
ATE447858T1 (en) PHARMACEUTICAL COMPOSITION FOR MUSCLE ANABOLISM
ES2538486T3 (en) Preparation of antigenic peptides against cancer
CY1114614T1 (en) BLOOD FLU ANTIGENS ANTIGONS AND DISTRIBUTED DNA FRAGMENTS
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
BRPI0514411A (en) formulation, and method of producing a formulation
ES2422081T3 (en) Peptide Ser-Ser-Ser-Arg and its medicinal uses
ECSP024257A (en) OLD PROTEINS OF THE VIRUS DISEASE OF THE WHITE SPOT DISEASE IN THE SHRIMP AND USES OF THE SAME
BR0213684A (en) Use of Endothelin Receptor Antagonists for the Treatment of Tumor Diseases
BR0009472A (en) Lhrh antagonists with improved solubility properties
BR0214363A (en) Antibody, use of an antibody, drug, method of manufacture of a drug and pharmaceutical package for the treatment of infection.
ATE205219T1 (en) AN IMPROVED PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR MEDICINAL PREPARATIONS, A METHOD FOR IMMUNIZING ANIMALS AGAINST THE HORMONE LHRH AND ANALOGUES OF THE LHRH TENDEM REPEAT PEPTIDE AND THEIR USE AS A VACCINE
BR0117149A (en) Use of a copolymer to produce a pharmaceutical form containing a peptide or protein as an active agent.
BR0109279A (en) Lhrh antagonists, their preparation and application as a medicine
DE60036199D1 (en) PROTEASERESISTENT FLINT ANALOG
BR0207077A (en) Terbinafine malic acid addition salts

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

Free format text: TRANSFERIDO DE: HARUO SUGIYAMA

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/47 (2006.01), A61K 39/00 (2006.01), A61P 3

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/08/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2715 DE 17-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.